Nov 14, 2025 07:05AM Monopar Therapeutics (MNPR) Misses Q3 EPS by 48c

Nov 14, 2025 05:06AM Raymond James Downgrades Monopar Therapeutics (MNPR) to Outperform

Nov 10, 2025 06:05AM Leerink Partners Starts Monopar Therapeutics (MNPR) at Outperform

Nov 10, 2025 04:52AM Monopar Therapeutics (MNPR) PT Raised to $100 at Chardan Capital Markets

Oct 13, 2025 05:30AM Barclays Starts Monopar Therapeutics (MNPR) at Overweight

Oct 10, 2025 07:24AM Jones Trading Assumes Monopar Therapeutics (MNPR) at Buy, PT $130

Oct 6, 2025 05:31AM Monopar Therapeutics (MNPR) PT Raised to $142 at Raymond James

Sep 29, 2025 08:05AM Monopar Therapeutics (MNPR) PT Raised to $105 at H.C. Wainwright

Sep 25, 2025 04:35PM Monopar Therapeutics (MNPR) PT Raised to $93 at Brookline Capital Markets

Sep 25, 2025 08:07AM Monopar Therapeutics (MNPR) PT Raised to $95 at Piper Sandler

Sep 24, 2025 03:53PM Monopar Therapeutics (MNPR) PT Raised to $104 at BTIG

Sep 24, 2025 04:51AM Monopar reports ALXN1840 improves copper balance in Wilson disease study

Sep 15, 2025 07:36AM H.C. Wainwright Reiterates Buy Rating on Monopar Therapeutics (MNPR)

Sep 9, 2025 08:12AM BTIG Starts Monopar Therapeutics (MNPR) at Buy

Sep 3, 2025 07:15AM Oppenheimer Starts Monopar Therapeutics (MNPR) at Outperform, PT $77

Aug 29, 2025 04:42PM Monopar Therapeutics (MNPR) Files $300M Mixed Shelf

Aug 27, 2025 06:49AM Cantor Fitzgerald Reiterates Overweight Rating on Monopar Therapeutics (MNPR)

Aug 26, 2025 06:34AM H.C. Wainwright Starts Monopar Therapeutics (MNPR) at Buy

Aug 12, 2025 04:01PM Monopar Therapeutics (MNPR) PT Lowered to $52 at Brookline Capital Markets

Jun 23, 2025 05:03AM Chardan Capital Markets Starts Monopar Therapeutics (MNPR) at Buy, PT $60

Jun 3, 2025 07:03AM Monopar Therapeutics (MNPR) Included in the Russell 3000 and Russell 2000 Indexes

May 13, 2025 04:22PM Monopar Therapeutics (MNPR) Tops Q1 EPS by 38c

Apr 2, 2025 07:08AM Jones Trading Downgrades Monopar Therapeutics (MNPR) to Hold

Mar 19, 2025 04:20AM Piper Sandler Assumes Monopar Therapeutics (MNPR) at Overweight

Jan 15, 2025 05:04PM Monopar Therapeutics (MNPR) Files for 882.76K Share Offering by Selling Stockholders

Jan 10, 2025 05:13AM Piper Sandler Starts Monopar Therapeutics (MNPR) at Overweight

Dec 20, 2024 09:01AM Monopar Therapeutics (MNPR) Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Nov 19, 2024 12:26PM Monopar Therapeutics (MNPR) PT Raised to $37 at Jones Trading

Nov 11, 2024 07:25AM Monopar Therapeutics (MNPR) PT Raised to $22 at H.C. Wainwright

Nov 8, 2024 04:13PM Monopar Therapeutics Inc. (MNPR) Misses Q3 EPS by 27c

Oct 29, 2024 06:00AM Monopar Therapeutics (MNPR) Prices $19.2M Share Offering at $16.25/sh

Oct 28, 2024 04:00PM Monopar Therapeutics (MNPR) Announces Proposed Share Offering

Oct 24, 2024 07:01AM Monopar Therapeutics (MNPR) Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

Oct 22, 2024 08:02AM Monopar Therapeutics (MNPR) Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

Sep 12, 2024 02:35PM Jones Trading Reiterates Buy Rating on Monopar Therapeutics (MNPR)

Sep 12, 2024 08:00AM Monopar Therapeutics (MNPR) Reports Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

Aug 27, 2024 04:06PM Monopar Therapeutics (MNPR) Regains Compliance with Nasdaq Minimum Bid Price Rule

Aug 21, 2024 08:00AM Monopar Therapeutics (MNPR) Cleared to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

Aug 12, 2024 06:56AM Monopar Therapeutics (MNPR) PT Raised to $6 at H.C. Wainwright

Aug 9, 2024 08:01AM Monopar Therapeutics (MNPR) Announces 1-for-5 Reverse Stock Split

Jul 24, 2024 09:33AM Jones Trading Assumes Monopar Therapeutics (MNPR) at Buy

Jun 11, 2024 07:31AM Monopar (MNPR) and NorthStar Amend & Extend Collaboration